Leerink Partnrs Comments on Pyxis Oncology FY2025 Earnings

Pyxis Oncology, Inc. (NASDAQ:PYXS) – Analysts at Leerink Partnrs reduced their FY2025 EPS estimates for Pyxis Oncology in a note issued to investors on Tuesday, November 25th. Leerink Partnrs analyst J. La. Rosa now anticipates that the company will post earnings of ($1.29) per share for the year, down from their previous estimate of ($1.26). The consensus estimate for Pyxis Oncology’s current full-year earnings is ($1.04) per share. Leerink Partnrs also issued estimates for Pyxis Oncology’s Q4 2025 earnings at ($0.29) EPS, Q1 2026 earnings at ($0.28) EPS, Q2 2026 earnings at ($0.30) EPS, FY2026 earnings at ($1.19) EPS, FY2027 earnings at ($1.33) EPS, FY2028 earnings at ($1.09) EPS and FY2029 earnings at ($0.34) EPS.

Pyxis Oncology (NASDAQ:PYXS) last issued its quarterly earnings results on Monday, November 3rd. The company reported ($0.35) EPS for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.01.

PYXS has been the topic of several other research reports. Zacks Research downgraded shares of Pyxis Oncology from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 4th. Wall Street Zen downgraded shares of Pyxis Oncology from a “hold” rating to a “sell” rating in a report on Friday, October 3rd. Stifel Nicolaus initiated coverage on shares of Pyxis Oncology in a research note on Monday, November 3rd. They issued a “buy” rating and a $9.00 price objective on the stock. Guggenheim raised their target price on shares of Pyxis Oncology from $5.00 to $7.00 and gave the stock a “buy” rating in a report on Tuesday, November 4th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Pyxis Oncology in a research report on Wednesday, October 8th. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $7.40.

Pyxis Oncology Stock Performance

Shares of PYXS stock opened at $5.15 on Thursday. Pyxis Oncology has a fifty-two week low of $0.83 and a fifty-two week high of $5.55. The firm has a market capitalization of $320.33 million, a PE ratio of -3.22 and a beta of 1.41. The stock’s 50-day simple moving average is $3.62 and its 200-day simple moving average is $2.10.

Institutional Trading of Pyxis Oncology

Institutional investors have recently bought and sold shares of the business. Schulhoff & Co. Inc. increased its position in shares of Pyxis Oncology by 125.4% in the second quarter. Schulhoff & Co. Inc. now owns 275,000 shares of the company’s stock valued at $302,000 after buying an additional 153,000 shares in the last quarter. Y Intercept Hong Kong Ltd acquired a new stake in Pyxis Oncology in the 2nd quarter valued at $146,000. 683 Capital Management LLC grew its stake in Pyxis Oncology by 32.5% in the 1st quarter. 683 Capital Management LLC now owns 550,000 shares of the company’s stock valued at $539,000 after acquiring an additional 135,000 shares during the period. Catalyst Funds Management Pty Ltd purchased a new stake in Pyxis Oncology in the 2nd quarter worth $26,000. Finally, Kingstone Capital Partners Texas LLC purchased a new stake in Pyxis Oncology in the 2nd quarter worth $37,000. 39.09% of the stock is owned by institutional investors and hedge funds.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.